Dermira Inc. (DERM) Given Positive Rating at Needham & Company LLC
Separately, Zacks Investment Research upgraded Dermira from a sell rating to a hold rating in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Dermira presently has a consensus rating of Buy and a consensus price target of $41.00.
Dermira (NASDAQ:DERM) opened at 34.97 on Monday. Dermira has a 12-month low of $17.42 and a 12-month high of $36.16. The firm’s market cap is $1.24 billion. The company has a 50-day moving average price of $32.92 and a 200-day moving average price of $29.32.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.03. On average, analysts predict that Dermira will post ($3.39) earnings per share for the current year.
In other news, insider Eugene A. Bauer sold 2,500 shares of Dermira stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $33.18, for a total transaction of $82,950.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Christopher M. Griffith sold 1,303 shares of Dermira stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $30.02, for a total value of $39,116.06. Following the transaction, the vice president now owns 44,941 shares in the company, valued at approximately $1,349,128.82. The disclosure for this sale can be found here. Insiders own 17.30% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in DERM. JPMorgan Chase & Co. boosted its stake in Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the last quarter. Glenmede Trust Co. NA purchased a new stake in Dermira during the second quarter valued at approximately $170,000. A.R.T. Advisors LLC purchased a new stake in Dermira during the second quarter valued at approximately $207,000. DIAM Co. Ltd. purchased a new stake in Dermira during the second quarter valued at approximately $231,000. Finally, Prudential Financial Inc. purchased a new stake in Dermira during the second quarter valued at approximately $253,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.